Human papillomavirus infections and vulvar disease development

Cancer Epidemiology Biomarkers and Prevention

Volumn 18, Issue 6, 2009, Pages 1777-1784

  Garland, Suzanne M ^a,b   Insinga, Ralph P ^c   Sings, Heather L ^c   Haupt, Richard M ^c   Joura, Elmar A ^d  

^a ROYAL WOMEN'S HOSPITAL   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c MERCK RESEARCH LABORATORIES   (United States)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; ARTICLE; CANCER GRADING; CANCER INCIDENCE; DISEASE COURSE; DISEASE DURATION; FEMALE; GENOTYPE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN PAPILLOMAVIRUS TYPE 33; HUMAN PAPILLOMAVIRUS TYPE 35; HUMAN PAPILLOMAVIRUS TYPE 39; HUMAN PAPILLOMAVIRUS TYPE 45; HUMAN PAPILLOMAVIRUS TYPE 51; HUMAN PAPILLOMAVIRUS TYPE 52; HUMAN PAPILLOMAVIRUS TYPE 56; HUMAN PAPILLOMAVIRUS TYPE 58; HUMAN PAPILLOMAVIRUS TYPE 59; HUMAN PAPILLOMAVIRUS TYPE 6; HUMAN TISSUE; MAJOR CLINICAL STUDY; PERINEUM; PRIORITY JOURNAL; RECTUM BIOPSY; VIRUS INFECTION; VULVA CANCER; WART VIRUS;

ADOLESCENT; ADULT; CANCER VACCINES; CARCINOMA IN SITU; DNA, VIRAL; DOUBLE-BLIND METHOD; FEMALE; HUMAN PAPILLOMAVIRUS 11; HUMAN PAPILLOMAVIRUS 16; HUMANS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; POLYMERASE CHAIN REACTION; PRECANCEROUS CONDITIONS; VULVAR NEOPLASMS;

EID: 67449107969     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-09-0067     Document Type: Article

References (32)

1. Newall A, Beutels P, Wood JG, Edmunds WJ, MacIntyre CR. Cost-effectiveness analyses of human papillomavirus vaccination. Lancet Infect Dis 2007;7:289-296 (Pubitemid 46414076)
2. Barnabas V, Kulasingam SL. Economic evaluations of human papillomavirus vaccines. Expert Rev Pharmacoeconomics Outcomes Res 2007;7:251-267 (Pubitemid 47192859)
3. Trimble C, Hildesheim A, Brinton LA, Shah KV, Kuter B. Heterogeneous etiology of squamous carcinoma of the vulva. Obstet Gynecol 1996;87:59-64. (Pubitemid 26015952)
4. Sutton BC, Allen RA, Moore WE, Dunn ST. Distribution of human papillomavirus genotypes in invasive squamous carcinoma of the vulva. Mod Pathol 2008;21:345-354 (Pubitemid 351304289)
5. Srodon M, Stoler MH, Baber GB, Kurman RJ. The distribution of low and high-risk HPV types in vulvar and vaginal intraepithelial neoplasia (VIN and VaIN). Am J Surg Pathol 2006;30:1513-1518 (Pubitemid 44808787)
6. Hampl M, Sarajuuri H, Wentzensen N, Bender HG, Kueppers V. Effect of human papillomavirus vaccines on vulvar, vaginal, and anal intraepithelial lesions and vulvar cancer. Obstet Gynecol 2006;108:1361-1368 (Pubitemid 44901008)
7. Monk BJ, Burger RA, Lin F, Parham G, Vasilev SA, Wilczynski SP. Prognostic significance of human papillomavirus DNA in vulvar carcinoma. Obstet Gynecol 1995;85:709-715
8. De Vuyst H, Clifford GM, Nascimento MC, Madeleine MM, Franceschi S. Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta-analysis. Int J Cancer 2009;124:1626-1636
9. Wheeler CM, Bautista OM, Tomassini JE, Nelson M, Sattler CA, Barr E. Safety and immunogenicity of co-administered quadrivalent human papillomavirus (HPV)-6/11/16/18 L1 virus-like particle (VLP) and hepatitis B (HBV) vaccines. Vaccine 2008;26:686-696
10. Garland SM, Steben M, Hernandez-Avila M, et al. Noninferiority of antibody response to human papillomavirus type 16 in subjects vaccinated with monovalent and quadrivalent L1 virus-like particle vaccines. Clin Vaccine Immunol 2007;14:792-795
11. The FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007;356:1915-1927 (Pubitemid 46740302)
12. Garland SM, Hernandez-Avila M, Wheeler CM, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007;356:1928-1943 (Pubitemid 46740303)
13. Villa LL, Costa RLR, Petta CA, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16 and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005;6:271-278
14. Mao C, Koutsky LA, Ault KA, et al. Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial. Obstet Gynecol 2006;107:18-27. (Pubitemid 43755499)
15. Joura EA, Leodolter S, Hernandez-Avila M, et al. Efficacy of a quadrivalent prophylactic humanpapillomavirus (types 6, 11, 16 and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three clinical trials. Lancet 2007;369:1693-1702
16. Sideri M, Jones RW, Wilkinson EJ, et al. Squamous VIN: 2004 modified terminology, ISSVD Vulvar Oncology Subcommittee. J Reprod Med 2005;50:807-810
17. Insinga RP, Dasbach EJ, Elbasha EH, Liaw KL, Barr E. Progression and regression of incident cervical HPV 6, 11, 16 and 18 infections in young women. Infect Agent Cancer 2007;2:15.
18. Jones RW, Rowan DM, Stewart AW. VIN: aspects of the natural history and outcome in 405 women. Obstet Gynecol 2005;106:1319-1326
19. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481
20. Efron B, Tibshirani RJ. An introduction to the bootstrap. New York: Chapman & Hall; 1993.
21. Joura EA. Epidemiology, diagnosis and treatment of VIN. Curr Opin Obstet Gynecol 2002;14:39-43.
22. Brown D, Kjaer SK, Sigurdsso , et al. The impact of quadrivalent HPV (type 6/11/16/18) L1 VLP vaccine on infection and disease due to oncogenic non-vaccine HPV types in generally HPV naive women aged 16-26. J Infect Dis 2009;199:926-935
23. Winer RL, Kiviat NB, Hughes JP, et al. Development and duration of human papillomavirus lesions, after initial infection. J Infect Dis 2005;191:731-738 (Pubitemid 40271061)
24. Woodman CB, Collins S, Winter H, et al. Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study. Lancet 2001;357:1831-1836 (Pubitemid 32539115)
25. Koutsky LA, Holmes KK, Critchlow CW, et al. A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection. N Engl J Med 1992;327:1272-1278
26. Rufforny I, Wilkinson EJ, Liu C, Zhu H, Buteral M, Massoll NA. Human papillomavirus infection and p16(INK4a) protein expression in VIN and invasive squamous cell carcinoma. J Low Genit Tract Dis 2005;9:108-113
27. Hillemanns P, Wang X. Integration of HPV-16 and HPV-18 DNA in VIN. Gynecol Oncol 2006;100:276-282
28. Gasco M, Sullivan A, Repellin C, et al. Coincident inactivation of 14-3-3σ and p16INK4a is an early event in vulval squamous neoplasia. Oncogene 2002;21:1876-1881 (Pubitemid 34259190)
29. Logani S, Lu D, Quint WG, Ellenson LH, Pirog EC. Low-grade vulvar and vaginal intraepithelial neoplasia: correlation of histologic features with human papillomavirus DNA detection and MIB-1 immunostaining. Mod Pathol 2003;16:735-741 (Pubitemid 37011067)
30. Skapa P, Zamecnik J, Hamsikova E, et al. Human papillomavirus (HPV) profiles of vulvar lesions: possible implications for the classification of vulvar squamous cell carcinoma precursors and for the efficacy of prophylactic HPV vaccination. Am J Surg Pathol 2007;31:1834-1843. (Pubitemid 350175810)
31. Feeny D, Furlong W, Boyle M, Torrance GW. Multiattribute Health-Status Classification Systems - Health Utilities Index. Pharmacoeconomics 1995;7:490-502.
32. Carter JJ, Madeleine MM, Shera K, et al. Human papillomavirus 16 and 18 L1 serology compared across anogenital cancer sites. Cancer Res 2001;61:1934-1940 (Pubitemid 32692010)